Georgia-based Inhibitex soared after the biopharmaceutical company reported a narrower third-quarter loss than estimated and said a clinical trial of a higher dose of INX-189, an oral treatment for chronic hepatitis C, showed no serious adverse events. The company said the drug, given at 200 milligrams once daily for a week, was potent and well tolerated in a recent clinical trial.
For more from BostonGlobe.com, sign up or log in below
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.